Securian Asset Management Inc lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 1.1% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 32,497 shares of the medical technology company’s stock after buying an additional 343 shares during the period. Securian Asset Management Inc’s holdings in Stryker were worth $6,681,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of SYK. BlackRock Inc. grew its position in Stryker by 0.6% during the 1st quarter. BlackRock Inc. now owns 25,036,303 shares of the medical technology company’s stock worth $4,945,168,000 after acquiring an additional 153,391 shares during the last quarter. FMR LLC grew its position in Stryker by 13.4% during the 1st quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock worth $1,328,951,000 after acquiring an additional 793,560 shares during the last quarter. Fundsmith LLP grew its position in Stryker by 1.0% during the 1st quarter. Fundsmith LLP now owns 5,581,841 shares of the medical technology company’s stock worth $1,102,525,000 after acquiring an additional 52,688 shares during the last quarter. Northern Trust Corp grew its position in Stryker by 1.2% during the 1st quarter. Northern Trust Corp now owns 3,903,582 shares of the medical technology company’s stock worth $771,036,000 after acquiring an additional 46,183 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Stryker by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 3,665,205 shares of the medical technology company’s stock worth $573,387,000 after acquiring an additional 224,785 shares during the last quarter. 74.14% of the stock is owned by institutional investors.

In other Stryker news, Director Srikant M. Datar sold 350 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $215.00, for a total value of $75,250.00. Following the sale, the director now owns 6,844 shares in the company, valued at approximately $1,471,460. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $217.08, for a total value of $1,012,895.28. The disclosure for this sale can be found here. Insiders sold a total of 20,447 shares of company stock worth $4,262,634 in the last quarter. Corporate insiders own 7.20% of the company’s stock.

Shares of NYSE SYK traded up $1.55 during trading on Wednesday, reaching $219.49. The company had a trading volume of 10,347 shares, compared to its average volume of 1,075,709. The company’s fifty day moving average price is $211.77 and its 200-day moving average price is $195.53. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $222.59. The stock has a market cap of $82.32 billion, a P/E ratio of 30.05, a PEG ratio of 2.63 and a beta of 0.85. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The firm had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.60 billion. During the same quarter in the previous year, the company posted $1.76 EPS. The business’s revenue was up 9.9% on a year-over-year basis. As a group, equities analysts predict that Stryker Co. will post 8.21 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.52 dividend. The ex-dividend date is Friday, September 27th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

A number of equities research analysts recently weighed in on the company. Barclays set a $226.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Raymond James set a $240.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Canaccord Genuity boosted their price objective on Stryker from $195.00 to $233.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Deutsche Bank boosted their price objective on Stryker from $181.00 to $208.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Royal Bank of Canada set a $220.00 price objective on Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. Five equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Stryker currently has a consensus rating of “Buy” and an average target price of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: Bear Market – How and Why They Occur

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.